

Benign Prostatic Hyperplasia Treatment Market Size, Trends, Analysis, and Outlook By Drug (Alpha Blockers, 5-Aplha Reductase Inhibitors, Others), By Surgical Treatment (Transurethral Resection of the Prostate (TURP), Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Laser Therapy, Prostatic Stenting, Others), by Country, Segment, and Companies, 2024-2032

https://marketpublishers.com/r/BBB1BC982891EN.html

Date: April 2024

Pages: 205

Price: US\$ 3,980.00 (Single User License)

ID: BBB1BC982891EN

Abstracts

The global Benign Prostatic Hyperplasia Treatment market size is poised to register 8.2% growth from 2024 to 2032, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Benign Prostatic Hyperplasia Treatment market across By Drug (Alpha Blockers, 5-Aplha Reductase Inhibitors, Others), By Surgical Treatment (Transurethral Resection of the Prostate (TURP), Transurethral Microwave Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Laser Therapy, Prostatic Stenting, Others)

The benign prostatic hyperplasia (BPH) treatment market is driven by the increasing prevalence of BPH, advancements in minimally invasive therapies, and the growing demand for effective and durable treatment options. By 2030, the market is anticipated to witness significant growth, fueled by innovations in prostate ablation devices, prostatic urethral lift systems, and combination therapies. Further, expanding applications in outpatient settings, urology clinics, and ambulatory surgery centers are expected to drive market expansion, offering patients minimally invasive alternatives to traditional BPH surgeries such as transurethral resection of the prostate (TURP) and



open prostatectomy.

Benign Prostatic Hyperplasia Treatment Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Benign Prostatic Hyperplasia Treatment market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Benign Prostatic Hyperplasia Treatment survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Benign Prostatic Hyperplasia Treatment industry.

Key market trends defining the global Benign Prostatic Hyperplasia Treatment demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Benign Prostatic Hyperplasia Treatment Market Segmentation- Industry Share, Market Size, and Outlook to 2032

The Benign Prostatic Hyperplasia Treatment industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Benign Prostatic Hyperplasia Treatment companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Benign Prostatic Hyperplasia Treatment industry

Leading Benign Prostatic Hyperplasia Treatment companies are boosting investments to capitalize on untapped potential and future possibilities across niche market



segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Benign Prostatic Hyperplasia Treatment companies.

Benign Prostatic Hyperplasia Treatment Market Study- Strategic Analysis Review

The Benign Prostatic Hyperplasia Treatment market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Benign Prostatic Hyperplasia Treatment Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Benign Prostatic Hyperplasia Treatment industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2032 in three case scenarios- low case, reference case, and high case scenarios.

Benign Prostatic Hyperplasia Treatment Country Analysis and Revenue Outlook to 2032

The report analyses 22 countries worldwide including the key driving forces and market size outlook from 2021 to 2032. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For



each of the six regions, the market size outlook by segments is forecast for 2032.

North America Benign Prostatic Hyperplasia Treatment Market Size Outlook-Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong healthcare infrastructure. Leading companies focus on new product launches in the changing environment. The US healthcare expenditure is expected to grow to \$4.8 trillion in 2024 (around 3.7% growth in 2024), potentially driving demand for various Benign Prostatic Hyperplasia Treatment market segments. Similarly, Strong market demand is encouraging Canadian Benign Prostatic Hyperplasia Treatment companies to invest in niche segments. Further, as Mexico continues to strengthen its relations and invest in technological advancements, the Mexico Benign Prostatic Hyperplasia Treatment market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Benign Prostatic Hyperplasia Treatment Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Benign Prostatic Hyperplasia Treatment industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of vendors in identifying and leveraging new growth prospects positions the European Benign Prostatic Hyperplasia Treatment market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Benign Prostatic Hyperplasia Treatment in Asia Pacific. In particular, China, India, and South East Asian Benign Prostatic Hyperplasia Treatment markets present a compelling outlook for 2032, acting as a magnet for both domestic and multinational vendors seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India



offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major countries in the APAC region.

Latin America Benign Prostatic Hyperplasia Treatment Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Benign Prostatic Hyperplasia Treatment Market Size Outlookcontinues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Benign Prostatic Hyperplasia Treatment market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Benign Prostatic Hyperplasia Treatment.

Benign Prostatic Hyperplasia Treatment Market Company Profiles

The global Benign Prostatic Hyperplasia Treatment market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Abbott Laboratories, AbbVie Inc, Advin Health Care, Alembic Pharmaceuticals Ltd, Allium Medical Solutions Ltd, Asahi Kasei Corp, Astellas Pharma Inc, biolitec AG, Boston Scientific Corp, Coloplast Group, Eli Lilly and Company, GlaxoSmithKline plc, IPG Photonics Corp, KARL STORZ SE & Co. KG, Lumenis Ltd, Medifocus Inc, Merck & Co. Inc, Olympus Corp, Pfizer Inc, Pharex HealthCorp Inc, Richard Wolf GmbH, Teleflex Inc, Unilab Pharmaceuticals Inc, Urologix LLC.

Recent Benign Prostatic Hyperplasia Treatment Market Developments

The global Benign Prostatic Hyperplasia Treatment market study presents recent



market news and developments including new product launches, mergers, acquisitions, expansions, product approvals, and other updates in the industry.

Benign Prostatic Hyperplasia Treatment Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2032 (Forecast

Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local

Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Drug

Alpha Blockers

5-Aplha Reductase Inhibitors

Others



By Surgical Treatment			
Transurethral Resection of the Prostate (TURP)			
Transurethral Microwave Thermotherapy (TUMT)			
Transurethral Needle Ablation of the Prostate (TUNA)			
Laser Therapy			
Prostatic Stenting			
Others			
Geographical Segmentation:			
North America (3 markets)			
Europe (6 markets)			
Asia Pacific (6 markets)			
Latin America (3 markets)			
Middle East Africa (5 markets)			
Companies			
Abbott Laboratories			
AbbVie Inc			
Advin Health Care			

Alembic Pharmaceuticals Ltd

Allium Medical Solutions Ltd



Asahi Kasei Corp

Astellas Pharma Inc	
biolitec AG	
Boston Scientific Corp	
Coloplast Group	
Eli Lilly and Company	
GlaxoSmithKline plc	
IPG Photonics Corp	
KARL STORZ SE & Co. KG	
Lumenis Ltd	
Medifocus Inc	
Merck & Co. Inc	
Olympus Corp	
Pfizer Inc	
Pharex HealthCorp Inc	
Richard Wolf GmbH	
Teleflex Inc	
Unilab Pharmaceuticals Inc	
Urologix LLC	



Formats Available: Excel, PDF, and PPT



Contents

1. EXECUTIVE SUMMARY

- 1.1 Benign Prostatic Hyperplasia Treatment Market Overview and Key Findings, 2024
- 1.2 Benign Prostatic Hyperplasia Treatment Market Size and Growth Outlook, 2021-2030
- 1.3 Benign Prostatic Hyperplasia Treatment Market Growth Opportunities to 2030
- 1.4 Key Benign Prostatic Hyperplasia Treatment Market Trends and Challenges
 - 1.4.1 Benign Prostatic Hyperplasia Treatment Market Drivers and Trends
 - 1.4.2 Benign Prostatic Hyperplasia Treatment Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Benign Prostatic Hyperplasia Treatment Companies

2. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SIZE OUTLOOK TO 2030

- 2.1 Benign Prostatic Hyperplasia Treatment Market Size Outlook, USD Million, 2021-2030
- 2.2 Benign Prostatic Hyperplasia Treatment Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

3. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
- * Threat of New Entrants
- * Threat of Substitutes
- * Intensity of Competitive Rivalry
- * Bargaining Power of Buyers
- * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET SEGMENTATION ANALYSIS AND OUTLOOK



- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030 By Drug

Alpha Blockers

5-APLHA REDUCTASE INHIBITORS

Others

By Surgical Treatment

Transurethral Resection of the Prostate (TURP)

Transurethral Microwave Thermotherapy (TUMT)

Transurethral Needle Ablation of the Prostate (TUNA)

Laser Therapy

Prostatic Stenting

Others

- 4.3 Growth Prospects and Niche Opportunities, 2023-2030
- 4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

- 5.1 Key Findings for Asia Pacific Benign Prostatic Hyperplasia Treatment Market, 2025
- 5.2 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size Outlook by Type, 2021- 2030
- 5.3 Asia Pacific Benign Prostatic Hyperplasia Treatment Market Size Outlook by Application, 2021- 2030
- 5.4 Key Findings for Europe Benign Prostatic Hyperplasia Treatment Market, 2025
- 5.5 Europe Benign Prostatic Hyperplasia Treatment Market Size Outlook by Type, 2021- 2030
- 5.6 Europe Benign Prostatic Hyperplasia Treatment Market Size Outlook by Application, 2021- 2030
- 5.7 Key Findings for North America Benign Prostatic Hyperplasia Treatment Market, 2025
- 5.8 North America Benign Prostatic Hyperplasia Treatment Market Size Outlook by Type, 2021- 2030
- 5.9 North America Benign Prostatic Hyperplasia Treatment Market Size Outlook by Application, 2021- 2030
- 5.10 Key Findings for South America Benign Prostatic Hyperplasia Treatment Market, 2025
- 5.11 South America Pacific Benign Prostatic Hyperplasia Treatment Market Size



Outlook by Type, 2021- 2030

- 5.12 South America Benign Prostatic Hyperplasia Treatment Market Size Outlook by Application, 2021- 2030
- 5.13 Key Findings for Middle East and Africa Benign Prostatic Hyperplasia Treatment Market, 2025
- 5.14 Middle East Africa Benign Prostatic Hyperplasia Treatment Market Size Outlook by Type, 2021- 2030
- 5.15 Middle East Africa Benign Prostatic Hyperplasia Treatment Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

- 6.1 US Benign Prostatic Hyperplasia Treatment Market Size Outlook and Revenue Growth Forecasts
- 6.2 US Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.3 Canada Market Size Outlook and Revenue Growth Forecasts
- 6.4 Canada Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
- 6.6 Mexico Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities



- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Benign Prostatic Hyperplasia Treatment Industry Drivers and Opportunities

7. BENIGN PROSTATIC HYPERPLASIA TREATMENT MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. BENIGN PROSTATIC HYPERPLASIA TREATMENT COMPANY PROFILES

- 8.1 Profiles of Leading Benign Prostatic Hyperplasia Treatment Companies in the Market
- 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
- 8.3 Financial Performance and Key Metrics



Abbott Laboratories

AbbVie Inc

Advin Health Care

Alembic Pharmaceuticals Ltd

Allium Medical Solutions Ltd

Asahi Kasei Corp

Astellas Pharma Inc

biolitec AG

Boston Scientific Corp

Coloplast Group

Eli Lilly and Company

GlaxoSmithKline plc

IPG Photonics Corp

KARL STORZ SE & Co. KG

Lumenis Ltd

Medifocus Inc

Merck & Co. Inc

Olympus Corp

Pfizer Inc

Pharex HealthCorp Inc

Richard Wolf GmbH

Teleflex Inc

Unilab Pharmaceuticals Inc

Urologix LLC.

9. APPENDIX

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information



I would like to order

Product name: Benign Prostatic Hyperplasia Treatment Market Size, Trends, Analysis, and Outlook By

Drug (Alpha Blockers, 5-Aplha Reductase Inhibitors, Others), By Surgical Treatment

(Transurethral Resection of the Prostate (TURP), Transurethral Microwave

Thermotherapy (TUMT), Transurethral Needle Ablation of the Prostate (TUNA), Laser Therapy, Prostatic Stenting, Others), by Country, Segment, and Companies, 2024-2032

Product link: https://marketpublishers.com/r/BBB1BC982891EN.html

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/BBB1BC982891EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html



To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$